# OnCo record paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024" ;
  schema:name "FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma"@en ;
  schema:description "Phase 2 or 3 results paper on Ciltacabtagene autoleucel in Multiple myeloma, in Clinical Cancer Research (2024), one of the most cited Europe PMC records with Ciltacabtagene autoleucel in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.ccr-24-0378>, <https://pubmed.ncbi.nlm.nih.gov/38713595/>, <https://europepmc.org/article/MED/38713595>, <https://clinicaltrials.gov/study/NCT03548207> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1158/1078-0432.ccr-24-0378> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Natrajan K, Kaushal M, George B, et al." ;
  onco:trials <https://onco.cc/trials/cartitude-1/> ;
  onco:journals <https://onco.cc/journals/clinical-cancer-research/> .